Search This Blog

Wednesday, January 29, 2020

Allergy Therapeutics’ peanut allergy vax encouraging action in animal model

UK-based Allergy Therapeutics (OTCPK:AGYTF) announces the publication of positive data on its peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology.
Results from a peanut allergy mouse model showed that the novel virus-like particle platform used in the vaccine candidate could treat the allergies and prevent anaphylaxis based on a single injection.
Peanut allergy-related tickers: Aimmune Therapeutics (NASDAQ:AIMT), DBV Technologies (NASDAQ:DBVT)
https://seekingalpha.com/news/3535635-allergy-therapeutics-peanut-allergy-vaccine-shows-encouraging-action-in-animal-model

Sorrento up 8% premarket on pact to develop coronavirus treatment

Sorrento Therapeutics (NASDAQ:SRNE) will collaborate with long-time partner Celularity to expand the therapeutic use of the latter’s allogeneic, off-the-shelf, placental-derived natural killer (NK) cell therapy, CYNK-001, to the prevention and treatment of coronavirus infection, focusing on the virus responsible for the current outbreak, 2019-nCoV.
The company says it is in contact with leading scientists and local Chinese experts to discuss the clinical validation and logistics required to fast track the candidate.
Sorrento owns 25% of Celularity.
Shares up 8% premarket on modestly higher volume.

Cytosorbents up 23% premarket on expanded use of CytoSorb in Europe

Thinly traded micro cap Cytosorbents (NASDAQ:CTSO) is up 23% premarket on modestly higher volume in reaction to its announcement that its blood purification device CytoSorb is now approved in the EU for the removal of anti-platelet agent ticagrelor (AstraZeneca’s Brilinta, Brilique) during surgery requiring cardiopulmonary bypass.
CytoSorb accounts for virtually all of the company’s revenues (~$5.6M in Q3 2019).
https://seekingalpha.com/news/3535664-cytosorbents-up-23-premarket-on-expanded-use-of-cytosorb-in-europe

Chimerix up 10% premarket on potential of brincidofovir in smallpox

Chimerix (NASDAQ:CMRX) is up 10% premarket on light volume in reaction to preclinical data that, it says, support the rationale of using brincidofovir to treat smallpox (and stockpiling as a countermeasure in the event of an outbreak). The results were presented at the ASM Biothreats Conference in Arlington, VA.
In two lethal animal models of smallpox, treatment with brincidofovir resulted in a statistically significant survival advantage compared to placebo.
The company plans to file a U.S. marketing application mid-year.
https://seekingalpha.com/news/3535683-chimerix-up-10-premarket-on-potential-of-brincidofovir-in-smallpox

DelMar Pharma up 16% premarket on positive VAL-083 data

Nano cap DelMar Pharmaceuticals (NASDAQ:DMPI) is up 16% premarket on modest volume on the heels of the publication of previously announced preliminary data from a single-arm, open-label Phase 2 study evaluating VAL-083, combined with radiotherapy, for the first-line treatment of newly-diagnosed patients with MGMT-unmethylated glioblastoma multiforme. The results are in the February issue of Glioma.
In 22 patients who completed at least one cycle of treatment, median progression-free survival (PFS) was 9.9 months (confidence interval: 7.3 - 12.0 months).
Median PFS was 10.4 months (CI: 6.0 - 12.0 months) in 18 patients who initially received the intended treatment dose.
An expansion phase will enroll up to 20 additional participants.
Orphan Drug-tagged VAL-083 (dianhydrogalactitol) is a small molecule chemotherapeutic, specifically, a bifunctional alkylating agent that kills cancer cells by breaking up DNA.
https://seekingalpha.com/news/3535708-delmar-pharma-up-16-premarket-on-positive-valminus-083-data

Intercept Pharma completes enrollment in late-stage NASH study

Intercept Pharmaceuticals (NASDAQ:ICPT) announces the completion of enrollment in a Phase 3 clinical trial, REVERSE, evaluating obeticholic acid (OCA) in NASH patients with compensated cirrhosis.
The primary endpoint is the proportion of patients achieving at least one-stage histological improvement in fibrosis with no worsening of NASH at month 18 versus placebo.
Participants who complete the double-blind phase will be eligible to enroll in an open-label extension study for up to an additional 12 months.
https://seekingalpha.com/news/3535693-intercept-pharma-completes-enrollment-in-late-stage-nash-study

Tuesday, January 28, 2020

Philips bids farewell to home appliances to sharpen health focus

Philips will complete its transformation to a health technology business with the sale of its domestic appliances division, which no longer fits with the company’s range of hospital equipment and personal health products.

Once a sprawling conglomerate, Amsterdam-based Philips has narrowed its focus in recent years, spinning off the lighting and consumer electronics divisions for which it was previously best known.
Philips said on Tuesday it would carve out the domestic appliances business, which produces coffee machines, vacuum cleaners and airfryers and generated 2.3 billion euros (£1.9 billion) in sales last year, in the coming 12 to 18 months.
“This business is not a strategic fit for our future as a health technology leader,” Chief Executive Officer Frans van Houten said.
He added that all options remained open for the division, which he said had a double-digit profit margin that was “slightly less” than the average for Philips.
ING analyst Marc Hesselink said a “quick and dirty” calculation valued the division at around 3 billion euros, assuming a 10% profit margin with a price tag of 12 times gross profit.
“This was a, in our view, widely expected move…to focus even more on health tech”, he said.
DISAPPOINTING RESULTS
Philips shares fell 3% in Amsterdam, with analysts pointing to fourth-quarter results that missed expectations, and disappointing sales growth in all sectors.
Comparable sales increased 3% to 6 billion euros from a year earlier, compared with an average forecast in a company poll of analysts for a 4.9% increase.
Adjusted earnings before interest, tax and amortisation (EBITA) rose 10% to 1.07 billion euros, also slightly below expectations.
Philips reaffirmed its 2020 targets for a 100 basis point improvement in adjusted EBITA margin and a 4 to 6% increase in comparable sales, but said it expected a slow start to the year with growth likely to be dented by China’s efforts to contain a coronavirus outbreak.
The company has around 8,000 employees in China, many of whom have been ordered by authorities to stay at home.
Philips fell far short of a similar 100 basis point profit margin improvement goal in 2019, having warned in October that it would miss the target as the U.S.-China trade war forced it to shift production and seek new suppliers.
The already struggling connected care business, which specialises in remote patient monitoring, was the hardest hit and Van Houten said that following a significant fall in margins, the division’s leader Carla Kriwet would leave the company and be replaced by Philips veteran Roy Jakobs.
Philips expects rising life expectancy and associated chronic diseases to increase demand for devices that allow patients to be monitored at home, but sales at the connected care unit have in recent years lagged those of bigger divisions selling large medical equipment and personal care devices.

https://www.marketscreener.com/ROYAL-PHILIPS-6289/news/Philips-bids-farewell-to-home-appliances-to-sharpen-health-focus-29899211/